MA49881B1 - Anticoprs anti cd25 optimisés dans leur partie fc impliquant la déplétion de cellules spécifiques aux tumeurs - Google Patents

Anticoprs anti cd25 optimisés dans leur partie fc impliquant la déplétion de cellules spécifiques aux tumeurs

Info

Publication number
MA49881B1
MA49881B1 MA49881A MA49881A MA49881B1 MA 49881 B1 MA49881 B1 MA 49881B1 MA 49881 A MA49881 A MA 49881A MA 49881 A MA49881 A MA 49881A MA 49881 B1 MA49881 B1 MA 49881B1
Authority
MA
Morocco
Prior art keywords
depletion
anticoprs
tumor
optimized
specific cells
Prior art date
Application number
MA49881A
Other languages
English (en)
Other versions
MA49881A (fr
Inventor
Anne Goubier
Pascal Merchiers
Josephine Salimu
Corzo Beatriz Goyenechea
Kevin Moulder
Sergio Quezada
Karl Peggs
Vargas Frederick Arce
Isabelle Solomon
Original Assignee
Cancer Research Tech Ltd
Tusk Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd, Tusk Therapeutics Ltd filed Critical Cancer Research Tech Ltd
Priority claimed from PCT/EP2018/056312 external-priority patent/WO2018167104A1/fr
Publication of MA49881A publication Critical patent/MA49881A/fr
Publication of MA49881B1 publication Critical patent/MA49881B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation d'un anticorps anti-cd25, qui n'inhibe pas l'interaction il-2-cd25, avec une liaison améliorée pour activer des rs gamma fc qui conduisent à un épuisement efficace de cellules treg infiltrant les tumeurs et une meilleure maîtrise de tumeurs établies. Selon l'invention, la combinaison avec des anticorps anti-protéine-1 de mort cellulaire programmée améliore en outre le rejet tumoral.
MA49881A 2017-03-17 2018-03-13 Anticoprs anti cd25 optimisés dans leur partie fc impliquant la déplétion de cellules spécifiques aux tumeurs MA49881B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17161717 2017-03-17
PCT/EP2018/056312 WO2018167104A1 (fr) 2017-03-17 2018-03-13 Anti-cd25 à optimisation fc pour épuisement de cellules spécifiques tumorales

Publications (2)

Publication Number Publication Date
MA49881A MA49881A (fr) 2020-06-24
MA49881B1 true MA49881B1 (fr) 2024-03-29

Family

ID=58387711

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49881A MA49881B1 (fr) 2017-03-17 2018-03-13 Anticoprs anti cd25 optimisés dans leur partie fc impliquant la déplétion de cellules spécifiques aux tumeurs

Country Status (2)

Country Link
MA (1) MA49881B1 (fr)
PT (1) PT3596123T (fr)

Also Published As

Publication number Publication date
MA49881A (fr) 2020-06-24
PT3596123T (pt) 2024-04-11

Similar Documents

Publication Publication Date Title
MA39313A1 (fr) Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
MA43075A1 (fr) Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers
MA43466A1 (fr) Traitements du cancer de l'utérus
MA42072A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre la cll et d'autres cancers
MX2019013033A (es) Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso.
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MA40713A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers
MA40497A (fr) Anticorps et récepteurs antigéniques chimériques spécifiques du cd19
EA201991156A1 (ru) АНТИТЕЛА К Tim-3 ДЛЯ КОМБИНАЦИИ С АНТИТЕЛАМИ К PD-1
MA43490A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers
MA44101B1 (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du sein et d'autres cancers
MX2019010974A (es) Compuestos y metodos para la reduccion celular especifica de tumor.
MA43719B1 (fr) Peptide à utiliser en immunothérapie contre le cancer du poumon non à petites cellules et le cancer du poumon à petites cellules
MA40813A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre diverses tumeurs
MA38498B1 (fr) Protéines de liaison anti-lag-3
MA43461A1 (fr) Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
MA42530B1 (fr) Constructions d'anticorps bispécifiques se liant à dll3 et à cd3
MA43477A1 (fr) Immunothérapie contre le mélanome et d'autres cancers
TN2019000294A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
MA50259A1 (fr) Stéroïdes et leurs conjugués-anticorps
CA2886433C (fr) Anticorps monoclonaux humains anti pd-l1 et procedes d'utilisation
NO20071790L (no) Fremgangsmater for anvendelse av dodsreseptorligander og CD20-antistoffer
MA43767B1 (fr) Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer
MA43482A1 (fr) Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre la leucémie myéloïde aiguë (lma) et d'autres cancers
EA200970607A1 (ru) Универсальная вакцина из опухолевых клеток для противораковой терапии и профилактического использования